Lineage Cell Therapeutics, Inc. – AMEX:LCTX
Lineage Cell Therapeutics stock price today
$1.25
+0.75
+151.51%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 6 hours
Lineage Cell Therapeutics stock price monthly change
-50.79%
month
Lineage Cell Therapeutics stock price quarterly change
-50.79%
quarter
Lineage Cell Therapeutics stock price yearly change
-57.88%
year
Lineage Cell Therapeutics key metrics
Market Cap | 122.61M |
Enterprise value | 228.43M |
P/E | -9.27 |
EV/Sales | 15.53 |
EV/EBITDA | -9.08 |
Price/Sales | 16.05 |
Price/Book | 3.28 |
PEG ratio | -0.21 |
EPS | -0.13 |
Revenue | 8.00M |
EBITDA | -23.84M |
Income | -23.65M |
Revenue Q/Q | -39.48% |
Revenue Y/Y | -32.47% |
Profit margin | -178.69% |
Oper. margin | -153.17% |
Gross margin | 95.05% |
EBIT margin | -153.17% |
EBITDA margin | -297.96% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLineage Cell Therapeutics stock price history
Lineage Cell Therapeutics stock forecast
Lineage Cell Therapeutics financial statements
| Jun 2023 | 3.22M | -5.22M | -162.14% |
|---|---|---|---|
| Sep 2023 | 1.24M | -7.11M | -570.63% |
| Dec 2023 | 2.08M | -4.77M | -228.69% |
| Mar 2024 | 1.44M | -6.54M | -453.05% |
| Mar 2024 | 1.44M | -6.54M | -453.05% |
|---|---|---|---|
| Sep 2025 | 744.5K | -7.76M | -1043.63% |
| Oct 2025 | 432.33K | -8.53M | -1974.36% |
| Dec 2025 | 432.33K | -9.14M | -2115.37% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 0.14% |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 111688000 | 40.43M | 36.2% |
|---|---|---|---|
| Sep 2023 | 106153000 | 39.49M | 37.2% |
| Dec 2023 | 101019000 | 38.99M | 38.6% |
| Mar 2024 | 108483000 | 37.49M | 34.56% |
| Jun 2023 | -6.26M | 19.15M | 5.62M |
|---|---|---|---|
| Sep 2023 | -5.03M | 2.12M | 807K |
| Dec 2023 | -6.01M | 9.74M | -13K |
| Mar 2024 | -5.78M | -38K | 14.02M |
Lineage Cell Therapeutics alternative data
| Aug 2023 | 70 |
|---|---|
| Sep 2023 | 70 |
| Oct 2023 | 70 |
| Nov 2023 | 70 |
| Dec 2023 | 70 |
| Jan 2024 | 70 |
| Feb 2024 | 70 |
| Mar 2024 | 68 |
| Apr 2024 | 68 |
| May 2024 | 68 |
| Jun 2024 | 68 |
| Jul 2024 | 68 |
Lineage Cell Therapeutics other data
29.43%
-8.93%
of LCTX is owned by hedge funds
68
-33
49.97M
-15.15M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 10000 | 0 |
| Feb 2024 | 6826925 | 0 |
| May 2024 | 10000 | 0 |
| Aug 2024 | 10500 | 0 |
| Nov 2024 | 110000 | 0 |
| Patent |
|---|
Application Filling date: 19 Sep 2019 Issue date: 25 Aug 2022 |
Application Filling date: 9 Dec 2021 Issue date: 2 Jun 2022 |
Application Filling date: 4 Apr 2017 Issue date: 27 May 2021 |
Application Filling date: 22 Jul 2020 Issue date: 8 Apr 2021 |
Grant Filling date: 18 Dec 2017 Issue date: 16 Feb 2021 |
Grant Utility: Methods for telomere length and genomic DNA quality control analysis in pluripotent stem cells Filling date: 23 May 2016 Issue date: 18 Aug 2020 |
Application Filling date: 19 Sep 2019 Issue date: 19 Mar 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Brian M. Culley M.A., M.B.A. (1971) Chief Executive Officer, Pres & Director | $828,350 |
| Ms. Brandi L. Roberts (1974) Consultant | $407,450 |
-
What's the price of Lineage Cell Therapeutics stock today?
One share of Lineage Cell Therapeutics stock can currently be purchased for approximately $1.25.
-
When is Lineage Cell Therapeutics's next earnings date?
Unfortunately, Lineage Cell Therapeutics's (LCTX) next earnings date is currently unknown.
-
Does Lineage Cell Therapeutics pay dividends?
No, Lineage Cell Therapeutics does not pay dividends.
-
How much money does Lineage Cell Therapeutics make?
Lineage Cell Therapeutics has a market capitalization of 122.61M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 39.16% to 8.95M US dollars.
-
What is Lineage Cell Therapeutics's stock symbol?
Lineage Cell Therapeutics, Inc. is traded on the AMEX under the ticker symbol "LCTX".
-
What is Lineage Cell Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Lineage Cell Therapeutics?
Shares of Lineage Cell Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Lineage Cell Therapeutics's key executives?
Lineage Cell Therapeutics's management team includes the following people:
- Mr. Brian M. Culley M.A., M.B.A. Chief Executive Officer, Pres & Director(age: 54, pay: $828,350)
- Ms. Brandi L. Roberts Consultant(age: 51, pay: $407,450)
-
How many employees does Lineage Cell Therapeutics have?
As Jul 2024, Lineage Cell Therapeutics employs 68 workers.
-
When Lineage Cell Therapeutics went public?
Lineage Cell Therapeutics, Inc. is publicly traded company for more then 33 years since IPO on 5 Mar 1992.
-
What is Lineage Cell Therapeutics's official website?
The official website for Lineage Cell Therapeutics is lineagecell.com.
-
Where are Lineage Cell Therapeutics's headquarters?
Lineage Cell Therapeutics is headquartered at 2173 Salk Avenue, Carlsbad, CA.
-
How can i contact Lineage Cell Therapeutics?
Lineage Cell Therapeutics's mailing address is 2173 Salk Avenue, Carlsbad, CA and company can be reached via phone at +44 22878990.
Lineage Cell Therapeutics company profile:
Lineage Cell Therapeutics, Inc.
lineagecell.comExchange:
AMEX
Full time employees:
68
Industry:
Biotechnology
Sector:
Healthcare
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
2173 Salk Avenue
Carlsbad, CA 92008
Carlsbad, CA 92008
CIK: 0000876343
ISIN: US53566P1093
CUSIP: 53566P109
